Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 9
Submit an article Journal homepage
32
Views
12
CrossRef citations to date
0
Altmetric
Review

Novel therapeutic agents under investigation for malignant melanoma

Anna C Pavlick New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA.
,
Sylvia Adams New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA.
,
Matthew A Fink New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA.
&
Amanda Bailes New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA.
Pages 1545-1558 | Published online: 02 Mar 2005

Bibliography

  • BALCH CM, BUZAID AC, SOONG SJ et al.: Final version of the American JointCommission on Cancer staging system for malignant melanoma.' Clin. Oncol (2001) 19:3635-3648. Revised American Joint Committee on Cancer staging now being used for melanoma.
  • BYSTRYN JC, SHAPIRO RL, ORATZ R: Cancer vaccines: clinical applications: partially purified tumor antigen vaccines. In: Biologic Therapy of Cancer (2nd edit). V DeVita, S Hellman, SA Rosenberg (Eds), J.B. Lippincott, Philadelphia, USA (1995):668–679.
  • PERALES MA, WOLCHOK JD: Melanoma vaccines. Cancer Invest. (2002) 20:1012–1026.
  • •Good overview of vaccine therapy.
  • DIFRONZO LA, GUPTA RK, ESSNER R et al.: Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. .1 Clin. OncoL (2002) 20(15):3242–3248.
  • HSUEH EC, ESSNER R, FOSHAG LJ et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. Clin. Oncol (2002) 20(23)4549–4554.
  • MITCHELL MS, DARRAH D, STEVENSON L: Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Cancer Invest. (2002) 20(5-6):759–768.
  • SONDAK VK, LIU PY, TUTHILL RJ et al.: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol (2002) 20(8):2058–2066.
  • •Intriguing paper addressing adjuvant therapy after resection of limited stage IV disease.
  • SOSMAN JA, UNGER JM, LIU PY et al: Adjuvant immunotherapy of resected, itermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol (2002) 20(8):2067–2075.
  • BHARDWAJ N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends MM. Med. (2001) 7(9):388–394.
  • ••Excellent review of DC biology andantigen uptake, processing and presentation.
  • BANCHEREAU J, STEINMAN R: Dendritic cells and the control of immunity. Nature (1998) 329:245–252.
  • ••An overview of the role of DC in initiationand modulation of immunity.
  • KEILHOLZ U, WEBER J, FINKE J et aL: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. Immunol (2002) 25(2):97–138.
  • DHODAPKAR M, STEINMAN R: Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood (2002) 100(1):174–177.
  • ARMSTORNG A: Cellular immunotherapy for cancer. Br. Med. (2001) 323:1289–1293.
  • TARTE K, KLEIN B: Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia (1999) 13:653–663.
  • SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev Immunol (2002) 2:151–161.
  • ••Detailed overview of DC subtypes inhumans.
  • STEFANOVIC S: Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev Cancer (2002) 2:514–520.
  • ZAROUR H, MAILLERE B, BRUSIC V, COVAL K, WILLIAMS E: NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Thl- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. (2002) 62:213–218.
  • ZENG G, TOULOUKIAN CE, WANG X,RESTIFO NP, ROSENBERG SA, WANG RF: Identification of CD4+ T-cell epitopes from NY-ESO-1 presented by HLA-DR molecules. I Immunol (2000) 165:1153–1159.
  • BROSSART P, WIRTHS S, BRUGGER W,KANZ L: Dendritic cells in cancer vaccines. Exp. HematoL (2001) 29:1247–1255.
  • NESTLE FO, ALIGJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
  • PANNELLI M, WUNDERLICH J, JEFFRIES J et al.: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gpiOO.j Immunol (2000) 23(4):487–498.
  • LAU R, WANG F, JEFFREY G et al.: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. Immunol (2001) 24(1):66–78.
  • THURNER B, HAENDLE I, RODER C et al.: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic celsl expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. Exp. Med. (1999) 190(11):1669–1678.
  • SCHULER-THURNER B, DIECKMANN D, KEIKAYOUSSI P et al.: Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. Immunol (2000) 165:3492–3496.
  • MACKENSEN A, HERBST B, CHEN J-L et al.: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. hat. Cancer (2000) 86(3):385–392.
  • BANCHEREAU J, PALUCKA A, DHODAPKAR M et al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. (2001) 61:6451–6458.
  • JONULEIT H, GIESECKE- TUETTENBERG A, TUTING T et al.: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection. Int. Cancer (2001) 93:243–251.
  • SCHULER-THURNER B, SCHULTZ E, BERGER T et al: Rapid induction of tumor-specific Type 1 helper cells in metastatic melanoma patients by vaccination with mature cryopreserved, peptide-loaded monocyte derived-dendritic cells. Exp. Med. (2002) 195(10):1279–1288.
  • YEE C, GREENBERG P: Modulating T-cell immunity to tumours: New strategies for monitoring T-cell responses. Nat. Rev Cancer (2002) 2:409–419.
  • KEILHOLZ U, WEBER J, FINKE J et al.: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. Immunol (2002) 25(2):97–138.
  • SRI VASTAVA PK: Interaction of heat shock proteins with peptides and with antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Ann. Rev. Immunol (2002) 20:395–425.
  • TAMURA Y, PENG P, LUI K, DAOU M, SRI VASTAVA PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278:117–120.
  • JANETZKI S, PALLA D, ROSENHAUERV, LOCHS H, LEWIS JJ, SRI VASTAVA PK: Immunization of cancer patients with autologous cancer-derived 1556 heat shock protein gp96 preparations: a pilot study. Int.' Cancer (2000) 88:232–238.
  • BELLI F, TESTORI A, LICIA R et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Clin. Oncol (2002) 20(20):4169–4180.
  • In: Biologic Therapy of Cancer (2nd edh V DeVita, S Hellman, SA Rosenberg (Eds), J.B. Lippincott, Philadelphia, USA (1995):251–254.
  • NOBLE S, GOA KL: Aldesleukin (Recombinant Interleukin-2). BioDrugs (1997) 7(5):394–422.
  • ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:907–913.
  • PHAN GQ, ATTIA P, STEINBERG SM, WHITE DE, ROSENBERG SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Clin. Oncol (2001) 19(15):3477–3482.
  • ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Stag. (1998) 228(3):307–319.
  • ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol (1999) 17(7):2105–2116.
  • •Important paper demonstrating the usefulness of HD IL-2.
  • ETON 0, LEGHA SS, BEDIKIAN AY et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. Clin. Oncol. (2002) 20(8):2045–2052.
  • KEILHOLZ U, GORE ME: Biochemotherapy for advanced melanoma. Semin. Oncol (2002) 29(5):456–461.
  • ATKINS MB: Interleukin-2: clinical applications. Semin. Oncol (2002) 29(3):12–17.
  • COLOMBO MP, VAGLIANI M, SPREAFICO F et al.: Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res. (1996) 56:2531–2534.
  • KIRKWOOD J: Cancer immunotherapy:the interferon-alpha experience. Semin. Oncol (2002) 29(3):18–26.
  • KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al: High- and low-dose interferon alfa-26 in high-risk melanoma: first analysis of intergroup trial E1690/ 59111/C9190. Clin. Oncol. (2000) 18(12):2444–2458.
  • •Cornerstone data for the use of HD IL in the US.
  • ROSENBERG SA, LOTZE MT, YANG JCet al.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. Clin. Oncol (1989) 7(12):1863–1874.
  • VAISHAMPAYAM U, ABRAMS J, DARRAH D, JONES V, MITCHELL MS: Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin. Cancer Res. (2002) 8(12):3696–3701.
  • HANSSON M, HENDERSON S, BRUNE M et al.: Histamine protects T-cells and natural killer cells against oxidative stress. Inteferon Cytokine Res. (1999) 19:1135–1144.
  • AGARWALA SS, GLASPY J, O'DAY SJ et al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. Clin. Oncol (2002) 20(1):125–133.
  • KRUMMEL ME SULLIVAN TJ, ALLISON JP: Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T-cell expansion M vitro and in vivo. Lit. Immunol (1996) 8(4):519–523.
  • CHAMBERS CA, SULLIVAN TL, ALLISON JP: Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CTLA-4+ T-cells. Immunity (1997) 7(6):885–895.
  • PEREZ VL, VAN PARIJS L, BIUCKIANS A, ZHENG XX, STROM TB, ABBAS AK: Induction of peripheral T-cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6(4):411–417.
  • VAN ELSAS A, HURWITZ AA, ALLISON JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Nati Acad. Sci. USA (1998) 95(17):10067–10071.
  • In: Biologic Therapy of Cancer Ond eduI V DeVita, S Hellman, SA Rosenberg (Eds), J.B. Lippincott, Philadelphia, USA (1995):534.
  • WILLIAM TG: Programmed cell death: apoptosis and oncogenesis. Cell (1991) 65:1097–1098.
  • NAKAYAMA K, NAKAYAMA K, NEGISHI I, KUIDA K, SAWA H, LOH DY: Targeted disrupting of Bc1-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc. Nati Acad. Sci. USA (1994) 91(9):3700–3704.
  • YAMAMURA K, KAMADA S, ITO S, NAKAGAWA K, ICHIHASHI M, TSUJIMOTO Y: Accelerated disappearance of melanocytes in bc1-2-deficient mice. Cancer Res. (1996) 56(15):3546–3550.
  • JANSEN B et al.: Systemic treatment with bc1-2 antisense down-regulates tumor content of bc1-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine. Proc. Ann. Meet. Am. Assoc. Cancer Res. (2000) 41:LB-23 (Abstract).
  • In: Cancer and the Search for Selective Biochemical Inhibitors. EJ Hoffman (Ed.), CRC Press, New York, USA (1999):367–368.
  • MARRIOTT JB, CLARKE IA, DREDGE K, MULLER G, STIRLING D, DALGLEISH AG: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol (2002) 130(1):75–84.
  • EISEN T, BOSHOFF C, MAK I et al.: Continuous low dose Thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. Cancer (2000) 82(4):812–817.
  • HWU WJ, KROWN SE, PANAGEAS KS et al.: Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol (2002) 20(11):2610–2615.
  • CORRAL LG, HASLETT PAJ, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. .1. Immunol (1999) 163:380–386.
  • BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157–1164.
  • MURRAY RZ, NORBURY C: Proteasome inhibitors as anti-cancer agents. Anti-Cancer Drugs (2000) 11:407–417.
  • BALDWIN AS: The NF-kappa B and I kappa proteins: new discoveries and insights. Ann. Rev Immunol (1996) 14:649–683.
  • AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505–2511.
  • PETTIS GR, HERALD CL, DOUBECK DL, HERALD DL: Isolation and structure of bryostatin-1. J. Am. Chem. Soc. (1982) 104:6846–6848.
  • ESA AH, BOTO WO, ADLER WH, MAY WS, HESS AD: Activation of T-cells by bryostatins: induction of the IL-2 receptor gene and down-modulation of surface receptors. hat. Immunopharmacol (1990) 12:481–490.
  • TOZER RG, BURDETTE-RADOUX S, BERLANGER K et al.: A randomized Phase II study of two schedules of bryostatin-1 (N5C339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs (2002) 20(4):407–412.
  • PAVLICK AC, HAMILTON A, LIEBES L et al.: Bryostatin 1 and Cisplatin: a Phase I and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol, San Francisco, USA (2001) (Abstract 328).
  • ALBERTS DS, HALLUM AV, STRATTON- CUSTISM et al.: Phase I pharmacokinetic trial and correlative in vitro Phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin. Cancer Res. (2001) 7(5):1246–1250.
  • LEGHA SS: Current therapy for melanoma. Semin. Oncol (1989) 16:34–44.
  • KHAYAT D, BERNARD-MARTY C, MERIC JB, RIXE 0: Biochemotherapy for advanced melanoma: maybe it is real. Clin. Oncol (2002) 20(10):2411–2414.
  • MIDDLETON MR, GROB JJ, AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol (2000) 18:158–166.
  • •Paper demonstrates equivalence of oral temozolomide to dacarbazine as single-agent treatment.
  • CHAPMAN PB, EINHORN LH, MEYERS ML et al.: Phase III multi-center randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol (1999) 17:2745–2751.
  • LEGHA SS, RING S, PAPADOPOULOS N et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 64:2024–2029.
  • ROWINSKY EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev Merl (1997) 48:353–374.
  • ETON 0, LEGHA SS, BEDIKIAN AY et al.: Sequential biochemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol (2002) 20(8):2045–2052.
  • RIDOLFI R, CHIARION-SILENI V, GUIDA M et al.: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-26 in advanced melanoma outpatients: results from an Italian multicenter Phase III randomized clinical trial. J. Clin. Oncol (2002) 20(6):1600–1607.
  • LEGHA SS, RING S, ETON 0 et al: Development of biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol (1998) 16:1752–1759.
  • MCDERMOTT DF, MIER JW, LAWRENCE DP et al.: A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alpha-2b in patients with metastatic melanoma. Clin. Cancer Res. (2000) 6:2201–2208.
  • ATKINS MB, LEE S, FLAHERTY LE, SOSMAN JA, SONDAK VK, KIRKWOOD JM: A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblatine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proceedings of the American Socieg, of Clinical Oncology Chicago, IL, USA (2003) 2847 (Abstract).
  • DEL VECCHIO M, BAJETTA E, VITALI M et al.: Multicenter Phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma. Proceedings of the American Socieg, of Clinical Oncology Chicago, IL, USA (2003) 2849 (Abstract).
  • SERRONE L, CATRICALA C, ZEULI M,COGNETTI F: 'Weekly' cisplatin and 'decrescendo' interferon-a schedule in advanced melanoma patients: Preliminary evidence for a new active combination. Proceedings of the American Society of Clinical Oncology,Chicago, IL, USA (2003) 2884 (Abstract).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.